top of page

AGTC Genomics Launches Expanded OncoDx™ Platform: Affordable, Scalable, and Market-Ready Cancer Genomics for Southeast Asia

  • Writer: cheeonnleong
    cheeonnleong
  • 7 days ago
  • 2 min read

AGTC Genomics, a leading precision medicine company in Southeast Asia, is proud to announce the official launch of its newly expanded OncoDx™ Comprehensive Gene Profiling (CGP) services, offering advanced genomic insights for both solid tumors and hematological malignancies at revised, more accessible pricing.


This launch reinforces AGTC Genomics' mission to make precision oncology affordable, accessible, and actionable for patients and clinicians throughout the region.


OncoDx™: Comprehensive, Flexible, and Future-Ready


The OncoDx™ platform leverages the latest next-generation sequencing (NGS) technologies and is fully validated under ISO 15189 and CAP-accredited laboratory standards. The newly launched offering now includes:


  • Up to 702-Gene Full Coding Sequence Panel (DNA + RNA)

Covers SNV, Indel, CNV, Gene Fusion, MSI, TMB, and HRR in a single comprehensive assay.


  • Wide Panel Selection for All Major Cancers

From pan-cancer CGP to 14 solid tumor-specific panels and 7 hematological panels, including tests for lung, breast, colorectal, AML, ALL, MPN, lymphoma, and sarcoma


  • Dual Sample Compatibility

Validated for use with both tumor tissue biopsies and liquid biopsies (blood-derived ctDNA), supporting applications from initial diagnosis to MRD (Minimal Residual Disease) monitoring.


  • Smart Upgrade Option

Clinicians can begin with a specific cancer panel and upgrade to full pan-cancer CGP by paying only the difference, minimizing unnecessary upfront costs.


  • Fast Turnaround Time

All tests are performed locally in Malaysia, with results delivered in 7–14 working days, ensuring timely and informed treatment decisions.



Empowering Clinicians, Supporting Patients


“OncoDx™ is not just a diagnostic tool—it’s a clinical decision-making partner,” said Prof. Dr. Chee-Onn Leong, CEO of AGTC Genomics. “With this expanded service, we are equipping oncologists with comprehensive molecular data that can guide targeted therapy and immunotherapy decisions, optimize treatment outcomes, and reduce the burden of trial-and-error medicine.”

AGTC Genomics continues to collaborate with hospitals, cancer centers, and academic medical institutions to drive the adoption of genomic profiling as a standard of care, supporting the region’s move toward personalized cancer care.



Availability


OncoDx™ is now available for order through AGTC Genomics’ network of clinical partners and can be accessed across Malaysia, Singapore, Vietnam, and the broader Southeast Asia region.


🔗 For more information or to request a test,

Email inquiries: info@agtcgenomics.com



About AGTC Genomics

AGTC Genomics is a Malaysia-based precision medicine company specializing in genomics, multi-omics diagnostics, and personalized health solutions. With internationally accredited laboratories and proprietary technology platforms, AGTC Genomics supports clinicians, researchers, and patients in transforming healthcare through genomic innovation.

Comments

bottom of page